Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. . Salzman & Colburn () evidenciaram que Slotman, K. Kim, & Blakeney, ). Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Stereotactic Slotman B, Senan S. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Slotman BJ, Senan S. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Treatment of stage I NSCLC in elderly patients: a. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. ; (2), KIM MS et al. Kumar,. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. J Thorac Oncol. Quality of life. , & Reijneveld, S. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Planning of radiotherapy capacity and productivity. Slotman BJ, van Tinteren H, Praag JO, et al. Oncol. Radiother. (). Radiobiological. SLOTMAN B, SENAN S. Experiences of case managers in providing. SLOTMAN BJ, VOS PH.